TVTX

Travere Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 3.14% likely due to the lack of revenue information and guidance. The cautious tone from management may have contributed to investor uncertainty about the company's future performance.